HNHA is a cell-permeable inhibitor of histone deacetylase (HDAC) activity. HNHA induces histone hyperacetylation and p21 transcription with inhibition of cell cycle progression in human fibrosarcoma HT1080 cells. In in vivo murine xenographs, HNHA is equally as effective as SAHA in inhibiting tumor growth. HNHA inhibits HUVEC growth and prevents tube formation and migration in response to VEGF. Also HNHA blocks retinal neovascularization and choroidal angiogenesis in mice.

≥98% by HPLC

HDAC is inhibited by HNHA with IC50 = 100 nM.

Soluble in ethanol, DMSO and dimethyl formamide at 20 mg/ml. Sparingly soluble in aqueous buffers. First dissolve in DMSO, then dilute with aqueous buffer of choice.

A crystalline solid

Store at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.

1. Kim, D.H., et al., Biochem. Biophys., Res. Commun. 2007; 356: 233 -328.
2. Kim, J.H., et al., Molecular Pharmaceutics 2009; 6(2): 513-519.

HDAC

Inhibitor